ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc (APLS)

27.95
0.57
(2.08%)
At close: October 15 4:00PM
27.95
-0.01
( -0.04% )
After Hours: 5:52PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

APLS News

Official News Only

APLS Discussion

View Posts
Monksdream Monksdream 1 month ago
APLS at a bottom channel
πŸ‘οΈ0
Dennisb68 Dennisb68 10 months ago
$60.00, that didn’t take long!
πŸ‘οΈ0
Dennisb68 Dennisb68 11 months ago
I like the way this traded today, $60 in the near future on news?
πŸ‘οΈ0
Dennisb68 Dennisb68 1 year ago
Holding up well..
πŸ‘οΈ0
doholic11 doholic11 1 year ago
Finally! Back up 14% today.
πŸ‘οΈ0
pitacorp pitacorp 1 year ago
Shorts got another 12 to 13% since you're warning, let's hope your warning sticks today...
πŸ‘οΈ0
Stockexpertpro Stockexpertpro 1 year ago
APLS Time to Cover Shorts just like i told the shorts last week on ARGX to Buy to Cover
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Closed out of puts at 99% profit on this one. Only three week hold.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Why is stock up so much???
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Stock up big today.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
FDA announcement soon.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Puts are very pricey and out of the money. Sell for cash to acct.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Why up today? As stock goes up, puts go up too. Strange.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Will we get FDA approval???
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Heavy premium in the puts and calls.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
2/8/23 regulatory decision due on Empavali.
πŸ‘οΈ0
conix conix 2 years ago
Huge Market

πŸ‘οΈ0
conix conix 2 years ago
Drug trial for dry AMD slows progression of disease

Posted: Tuesday 29 March 2022

A drug being trialled for dry age-related macular degeneration (AMD) can significantly reduce the progression of the disease, according to new studies.

Phase three trials have shown that injections of a drug called pegcetacoplan resulted in a significant reduction in the rate at which the cells of the macular degenerate.

The studies by Apellis Pharmaceuticals built on previous research which showed that dry AMD is linked to the complement system and a hyperactive immune response that damages the eyes. Pegcetacoplan is a complement system inhibitor, meaning it aims to prevent this response from happening and harming healthy cells and tissue.

The studies involved two phase three clinical trials (DERBY and OAKS) involving more than 1,250 patients with late stage dry AMD, often referred to as geographic atrophy (GA). As part of the trials some patients received injections monthly, while others received them every other month.

In the combined results of the two trials, patients who received the drug monthly showed up to a 21% reduction in progression of the disease after 18 months, while those who were injected every other month had a 17% reduction.

Jeffrey S. Heier, principal investigator of the DERBY study from Ophthalmic Consultants of Boston, said: β€œIt is exciting to see these positive data with pegcetacoplan, which showed continuous and potentially improving effects over time. These 18-month results provide further evidence that pegcetacoplan meaningfully slows disease progression and has the potential to preserve vision longer.”

He added: β€œIn my practice, I have seen how devastating it can be for people living with GA to lose more of their vision year after year. There is an urgent unmet need in GA, and these results reinforce the potential of pegcetacoplan to become the first-ever treatment for patients with this debilitating disease.”

The study also found that pegcetacoplan was generally safe and well tolerated by those on the trial.

Results of the studies are to be submitted to the US Food and Drug Administration (FDA) for review by the end of June 2022, with the hope that the drug will be licenced for use in the USA.
πŸ‘οΈ0
PickleNick PickleNick 3 years ago
Going back to 60 this week
πŸ‘οΈ0
wantprofits wantprofits 5 years ago
looks like insider dumping may be happening again.. damnit
πŸ‘οΈ0
Pedro2004 Pedro2004 5 years ago
Be careful with this company.
There was a great PR.
An insider dump.
Then a 7 million share under-market private placement.
Then another insider dump the next day.

Scam company.
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $APLS Video Chart 01-07-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ComptonBrosInc ComptonBrosInc 5 years ago
First! Holding $40 2/21 call... waiting on trial results!
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock